Phase II Trial of Chemotherapy With Temodar With Topotecan for CNS Metastasis of Solid Tumors

Inclusion Criteria:

To be eligible for the study, patients must have evidence of progressive CNS metastases of a solid tumor (new or progressing lesions), and either:

1. Have failed prior WBRT.
2. Or: not be candidates for surgical intervention and not require immediate radiation therapy to relieve symptoms, and have controlled systemic disease.

Additional requirements:

1. Patients must be > 18 years old.
2. Patients must have radiographically measurable tumor on the updated scan within 2 weeks prior to starting treatment.
3. Patients must have histopathologic documentation of primary tumor at the time of initial diagnosis.

4. Patients must be in adequate condition at time of enrollment, as indicated by:

   1. Absolute neutrophil count (ANC) greater than or equal 1,500/mm3
   2. Hemoglobin greater than or equal 9 gm/dL
   3. Platelets greater than or equal 100,000/mm3
   4. Karnofsky Performance Status greater than or equal 50
   5. Creatinine clearance >40 ml/min
   6. Total bilirubin less than or equal 2.0 mg/dl and SGOT, SGPT less than or equal 3 times upper limit of normal

5. Patients must not be receiving concurrent anti-tumor therapy and must have recovered from toxicity of prior therapy. Minimum intervals required:

   1. greater than or equal 6 weeks after receiving nitrosourea cytotoxic drug
   2. greater than or equal 4 weeks after receiving any non-nitrosourea cytotoxic drug or any systemic investigational agent with exception of methotrexate
   3. greater than or equal 2 weeks after receiving methotrexate
   4. greater than or equal 2 weeks after receiving any non-cytotoxic anti-tumor drug.
   5. greater than or equal 4 weeks after radiation therapy or SRS.
   6. greater than or equal 3 weeks after craniotomy or other surgery.
6. Female patients of childbearing potential must have a negative pregnancy test at the time of screening. All patients must be willing to practice an effective method of birth control during the study. Female patients must not be pregnant or breast-feeding during the entire study.
7. Patients or legal representatives must understand the investigational nature of this study and sign a written informed consent form, approved by the Institutional Review Board (IRB) prior to enrolling into the study.
8. No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years.

Exclusion Criteria:

1. Patients who are pregnant or breastfeeding, or females of childbearing potential not using adequate contraception.
2. Known allergy to temozolomide or topotecan.
3. Severe vomiting or other inability to administer medications orally.
4. Major medical illnesses or psychiatric impairment that in the investigator's opinion will prevent administration or completion of the protocol therapy and/or will interfere with follow-up.